Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.12 USD | -1.29% | +1.84% | -10.98% |
05-16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
05-02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.98% | 271M | |
+11.19% | 226B | |
+14.97% | 198B | |
+18.77% | 142B | |
+29.63% | 111B | |
+2.40% | 65.26B | |
+17.29% | 54.36B | |
+4.96% | 50.94B | |
+8.95% | 44.8B | |
+3.43% | 36.8B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- AxoGen Expects Revenue Increase in Q4, Full Year of 2022